Zimbabwe has declined a significant American health deal valued at $367m (272 million pounds) over five years because of Washington's demand for sensitive information.
This rejection came to light after a official document from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
An official spokesperson later clarified that the United States was demanding access to genetic material for research and commercial gain but was not willing to share the resulting advantages from any future treatments.
"We are forced to start the difficult and regrettable process of winding down our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had furnished more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more dialogue to find a deal suitable to all parties so the country's critical HIV programme can proceed.
Wider Background
This development follows a comparable situation in neighbouring Kenya, where a high court suspended a related health funding agreement after concerns were raised about the safety of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government deals to enhance transparency and responsibility.
As per reports, Sixteen nations in Africa have so far agreed to similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration would have delivered immense advantages for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no equivalent promise of benefiting from any medical innovations – such as new medicines or tests – that might result from that shared data," his statement read.
"Effectively, our country would provide the basic resources for scientific discovery without any assurance that the final treatments would be accessible to our population if a future health crisis emerge."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the global health body and its push of bilateral health agreements were upending structures previously established through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework created to deal with future global health emergencies.
"This system is designed to guarantee that when a nation contributes its data, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome ongoing discussions with our American counterparts on how subsequent co-operation could be arranged in a manner that honours the independence and dignity of both nations."
Health Experts Reaction
Medical experts stated it recognised the government's concerns, but recommended that talks must proceed considering much of the nation's Aids initiatives were funded by foreign aid.
"Where technical issues exist, including those involving information security or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," it said.
This impasse highlights the ongoing challenges between receiving vital international aid and protecting local interests in an ever more data-driven world.